BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting CXCR3, CXCL9 for osteoporosis

DISEASE CATEGORY: Musculoskeletal INDICATION: Osteoporosis Inhibiting the chemokine receptor CXCR3 or its ligand CXCL9 could treat osteoporosis. In a medaka fish model of RANKL-induced osteoporosis, two CXCR3 inhibitor tool compounds reduced mineralization defects including resorption...
BioCentury | Sep 11, 2019
Financial News

BioNTech IPO filing says trade war, Hong Kong unrest may be delaying $100M of series B

BioNTech’s IPO filing revealed that it has not yet received $100 million from a Hong Kong-based investor who was part of its recent $325 million series B round, likely because of “disruptions” in Hong Kong...
BioCentury | Jul 11, 2019
Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

Tumor mutation burden is looking less like a magic bullet and more like just one of at least three variables that could jointly predict responses to checkpoint inhibitors. Combining TMB measurements with markers of T...
BioCentury | Jun 1, 2018
Clinical News

Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional survival data from the Phase III IMpower150 trial evaluating Tecentriq atezolizumab in 1,202 chemotherapy-naïve patients with advanced stage IV non-squamous non-small cell lung cancer (NSCLC)....
BioCentury | Dec 22, 2017
Product Development

Beyond PD-L1 assays

Data from Genentech Inc.’s Phase III IMpower150 trial of Tecentriq atezolizumab in first-line non-small cell lung cancer provides the company with its first hard data showing what work lies ahead before it will be ready...
BioCentury | Dec 15, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab (MPDL3280A, RG7446) as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC),...
BioCentury | Dec 7, 2017
Clinical News

Genentech reports detailed data for Tecentriq in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported detailed data from the Phase III IMpower150 trial of Tecentriq atezolizumab as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer, including results from...
BioCentury | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BioCentury | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
Items per page:
1 - 10 of 59